Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test by Yoshihiro Miyashita, MD, Yosuke Hirotsu, PhD, Yuki Nagakubo, MS, Hiroaki Kobayashi, MD, Makoto Kawaguchi, MD, Koki Hata, MD, Ryota Saito, MD, Yumiko Kakizaki, MD, Toshiharu Tsutsui, PhD, Toshio Oyama, MD, Masao Omata, MD

Get full text